New drug combo aims to shrink Hard-to-Treat tumors

NCT ID NCT06848699

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced or metastatic solid tumors, including non-small cell lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults aged 18 to 75 who have not responded to standard treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER SOLID TUMOR CANCER

Contacts and locations

Locations

Hunan Provincial Cancer Hospital
RECRUITING

Hunan, Changsha, 410031, China
Second Affiliated Hospital of Army Medical University, PLA
RECRUITING

Chongqing, 400000, China
Shandong Cancer Hospital
RECRUITING

Jinan, Shangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.